Michael Foley
@MikeFoley89
Followers
268
Following
253
Media
3
Statuses
51
Cardiology Registrar | MRC Clinical Research Training Fellow | Imperial College London
London, England
Joined September 2010
RT @RahulBahl3: Excellent presentation by @MikeFoley89 at #TCT2024 on physiology stratified analysis of ORBITA-2. FFR and iFR clearly predi….
0
3
0
RT @ShaynaChotai: It was such a pleasure to join @rallamee to talk all things ESC 2024.Thank you so much @TheLancet #chloewilson . https://….
open.spotify.com
The Lancet in conversation with · Episode
0
3
0
RT @pajhaworth: Cardiology research is “on FiRE” in Portsmouth today. 2 wonderful cases using in depth coronary physiology and imaging as p….
0
9
0
RT @RCoANews: 🎉New NovPods! . This time @DoreEoin and Dr Duncan Kemp are joined by @RosannaEGrimes to navigate us through the world of obs….
0
9
0
RT @rajkumar_chris: Should PCI be an option for first line management of stable angina symptoms? . Point and counterpoint in @CircOutcomes….
0
17
0
RT @DrPeterOKane: 🙏🏻 @rallamee for coming to @UHD_NHS today to proctor our first 4 coronary sinus reducer cases @ShockwaveIVL . Great to ge….
0
6
0
RT @rajkumar_chris: Check out our journal club with @OPCILive on ORBITA-STAR and the symptom stratified analysis of ORBITA-2 @rallamee @Flo….
0
4
0
RT @rallamee: Just in case you thought the ORBITA team had gone on summer vacation… The first ORBITA-MOON case was completed yesterday. Ano….
0
12
0
RT @danmckenzie73: Thanks to @drtimwells and the @SalisburyDistr1 Cathlab team for making me so welcome. 2 patients now with coronary sinus….
0
4
0
Proud of my friend @rajkumar_chris presenting the game changing ORBITA-STAR trial on the main stage at #EuroPCR2024. EuroPCR’s got talent winner - well deserved against excellent competition. @rallamee @mshunshin
2
2
44
The symptom stratified analysis of ORBITA2 and the ORBITA-STAR trial both presented at #EuroPCR2024 and simultaneously published in @JACCJournals by @FloSimader and @rajkumar_chris. PCI isn’t a therapy for all symptoms, it’s a therapy for angina @rallamee @mshunshin
0
19
56
RT @f2harrell: Proud to be a co-author with @rallamee @mshunshin on a 100% Bayesian clinical trial paper that also uses our latest longitud….
thelancet.com
ORBITA-COSMIC found no evidence that the CSR improved transmural myocardial perfusion, but the CSR did improve angina compared with placebo. These findings provide evidence for the use of CSR as a...
0
34
0
RT @fiyyazAJ: Incredibly proud to celebrate @rallamee being awarded the Global CV Future Leader Award 2024 #GCVAwards. An exceptional mento….
0
3
0
I’m delighted to see our paper highlighted by TCT MD. Our belief in a therapy is associated with how intuitive it seems. This may subconsciously influence the threshold we set for randomised data. We should keep this in mind as we appraise procedures, new and old. @rallamee.
Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective
1
5
17
RT @DoreEoin: 🚨 🚨 .Please share with starting Novices for a warm welcome into the world of anaesthesia. The links have some feedback on the….
0
10
0
Delighted to see our ORBITA-COSMIC design paper published in Eurointervention. Now for the results! My thanks as ever to my supervisors and the incredible ORBITA team @rallamee @mshunshin @rajkumar_chris @fiyyazAJ @FloSimader @drgrahamcole @ProfDFrancis.
Have you already metabolized the outcomes of ORBITA 2? Next stop in the ORBITA program is called ORBITA-COSMIC. The coronary sinus Reducer (CSR) is an hourglass-shaped device which creates an artificial stenosis in the coronary sinus. The ORBITA-COSMIC trial is a randomized,
0
4
31
RT @rallamee: There is an unsung hero in the ORBITA family and we don’t do forgotten heroes. @mshunshin is the cleverest man I know and res….
0
14
0
I’m incredibly proud to have played a part in ORBITA2, presented brilliantly today by Chris Rajkumar at #AHA23. Rasha Al-Lamee has shown not only that PCI works, but so too does academic mentorship, authentic leadership and empowering her fellows. Can’t wait for the next one
5
16
132